Indapta Therapeutics Granted FDA Fast Track Designation for Natural Killer Cell Therapy for Hematologic Malignancies

IDP-023 is a highly potent natural killer cell platform under evaluation for patients with multiple myeloma and non-Hodgkin lymphoma.

Source link
#Indapta #Therapeutics #Granted #FDA #Fast #Track #Designation #Natural #Killer #Cell #Therapy #Hematologic #Malignancies